"What's New" Giveaway Announcement

Orange Book Insights No. 28:  I recently thought of a new way to introduce users of the FDA’s “Orange Book” to my enhanced alternative, the Orange Book Companion ® (“OBC”) . I am doing this by giving something away for free. This is something that everyone who is interested in Orange Book patent and exclusivity information will be able to access, and I intend to continue providing this free information at least through 2022. So, what am I giving away? It is the  OBC ’s monthly “ What’s New ” file, currently based, a s of the Jan. 15, 2022 publication of this blog posting,  on Volume 41, Supplement No. 12 of the  FDA’s monthly PDF Orange Book  Cumulative Supplement . Each month the OBC' s " What's New " will change  as the FDA publishes their monthly Cumulative Supplements . The OBC 's  What’s New  file is a highly enhanced alternative to the “ Patent And Exclusivity Drug Product List ” found in each FDA monthly Cumulative Supplement .   Until now the  OBC ’s month

Mystery: is there a difference between ASTEPRO ALLERGY and Children’s ASTEPRO ALLERGY?

  Orange Book Insights No. 27 –  Mystery: is there a difference between ASTEPRO ALLERGY and Children’s ASTEPRO ALLERGY ? Two nasal sprays containing azelastine hydrochloride were approved under NDA 213872 on June 17, 2021. They were named ASTEPRO ALLERGY (Prod. No. 001) and  Children’s  ASTEPRO ALLERGY (Prod. No. 002). Both have a strength of 0.2055mg/spray. The directions for use are also identical. For example, Prod. No. 001 has the same directions for use by children as Prod. No. 002. Similarly, Prod. No. 002 has the same directions for use by adults as Prod. No. 001. The inactive ingredients of the two versions are identical and listed in the same order. What brought these products to my attention was the Supplement 7 “What’s New” of my Orange Book Companion . The “What’s New” showed that, after the June 17 approval of the both products, three patents were listed for Prod. No. 001, but none for the Prod. No. 002 “children’s” version. The claims of the three listed patents did not

Orange Book Insights No. 26: Interesting New Patents From FDA''s Orange Book: Vol. 41, Supplement 3

Is a method of preventing certain patients from receiving a drug a “method of using” the drug? Patents directed to computerized methods of preventing a patient from receiving a drug have previously been listed in the Orange Book. Most notable are patents listed by Celgene for their thalidomide product, THALOMID®. Thalidomide can cause significant birth defects if a woman takes the drug while pregnant. The Celgene patents were directed to a computer system meant to prevent a pharmacy from selling THALOMID to a woman who has not had a recent negative pregnancy test. So when I saw that the “What’s New” for Supplement 3 of my Orange Book Companion ® showed that Zogenix had listed a patent with computer system claims for their FINTEPLA® (fenfluramine) product, I thought of one of Yogi Berra’s famous witticisms: “it’s déjà vu all over again”! Why might FINTEPLA have a computer system patent? Fenfluramine was part of an infamous diet drug combo called “fen-phen” in the 1990’s. Fen-phen was bl

Dreams Do Come True: The Purple Book is getting patent listings!

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) did not contain any provisions for patent listings for the products covered by the Act. That was a big difference between the BPCIA and Hatch-Waxman. As an Orange Book patents aficionado and the creator of the   Orange Book Companion ® ( OBC ) , I had dreamed over the years of somehow collecting patents on biologics and creating a Purple Book Companion ™ ( PBC ). My plan would be for the   PBC   to provide enhanced info for biologics patents in the same way that my   Orange Book Companion   provides enhanced info for small molecule drug patents. You can see samples of the   OBC ’s enhanced format on the   OBC  public homepage .   Well, my dream may be about to come true! A January 15, 2021 alert from the  Arent Fox firm  described a three-page section of the 2,124-page “Consolidated Appropriations Act, 2021” (“the Act,” enacted December 27, 2020) which is entitled “Sec. 325 Biological Product Patent Transparency”. At pa

Parts is Parts? A few thoughts about some of the comments that were submitted to the FDA about Orange Book listings

The deadline for submitting comments to the FDA about patent listings in the Orange Book has long passed. The result was the submission of seventeen comments by a variety of organizations.   A big issue discussed in the comments is the eligibility for listing in the Orange Book of patents that claim a drug administration device or a part thereof. This issue can be broken down into:   1) for a patent claiming the device as a whole, does there have to be a claim that recites the presence of a drug (or “the” drug) in the device in order to make the patent eligible for listing in the Orange Book?   2) is a patent that claims only an individual part of the device eligible for listing in the Orange Book?   Presence of “a” drug or “the” drug ?                Presence of “a” drug ?   Yes, patent attorneys have drafted claims for patent administration devices that, even when they know that the device was designed with a particular active ingredient in mind, do not include a drug as an element i